2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriers
2021
Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine
Du CX, Shi J, Tetrault JM, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice 2021, 39: 234-240. PMID: 34893825, PMCID: PMC8947790, DOI: 10.1093/fampra/cmab166.Peer-Reviewed Original ResearchConceptsOffice-based opioid treatmentPrimary care providersOpioid use disorderUrine toxicologyOpioid treatmentMore primary care providersOutpatient primary care clinicsChronic pain statusChronic viral hepatitisPrimary care clinicsCommon comorbid conditionsPrimary care characteristicsAddiction treatment settingsHigher median numberEvidence-based treatment modelsOBOT patientsOBOT programOlder patientsPain statusViral hepatitisCommon medicationsRetrospective reviewCare clinicsChronic painComorbid conditions
2013
Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist Treatment
Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist Treatment. Journal Of Addiction Medicine 2013, 7: 102-107. PMID: 23388678, PMCID: PMC3618545, DOI: 10.1097/adm.0b013e31827f9bdf.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentTransmission risk behaviorsHIV transmission risk behaviorsInjection drug useAgonist treatmentARV resistanceRisk behaviorsDrug useAntiretroviral resistanceUrine toxicologyClass resistanceSelf-reported HIV risk behaviorsTriple-class resistanceOpioid treatment programsPositive urine toxicologyOpioid-dependent individualsPercent of subjectsHIV risk behaviorsCross-sectional studyResource limited settingsIllicit drug useHIV seroconversionRisky sexual behaviorHIV resistanceResistant viruses